Safety and efficiency of therapy with modern preparations of idiopathic pulmonary fibrosis

Safety and efficiency of therapy with modern preparations of idiopathic pulmonary fibrosis

This review reviews the efficacy and safety of therapy with tyrosine kinase inhibitors and pyrphenidone in idiopathic pulmonary fibrosis. The results of randomized trials of recent years are described in detail. The efficacy of taking tyrosine kinase inhibitors at the following key research points i...

Full description

Bibliographic Details
Main Author:	E. A. Strel’tsov
Format:	Article
Language:	English
Published:	State Budget Educational Institute of Higher Professional Education, Rostov State Medical University, Ministry Health of Russian Federation 2018-03-01
Series:	Медицинский вестник Юга России
Subjects:	tyrosine kinase inhibitor idiopathic pulmonary fibrosis nintedanib overview interstitial lung disease
Online Access:	https://www.medicalherald.ru/jour/article/view/631

Similar Items

Idiopathic pulmonary fibrosis: the turning point is now!
by: Manuela Funke, et al.
Published: (2015-05-01)

Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis
by: James Patrick Finnerty, et al.
Published: (2021-12-01)

Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic countries
by: Ida Pesonen, et al.
Published: (2018-05-01)

Pharmacological treatment of idiopathic pulmonary fibrosis and fibrosing interstitial lung diseases: current trends and future directions
by: Won-Il Choi
Published: (2021-03-01)

South–West of England’s Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
by: Shaney L. Barratt, et al.
Published: (2018-12-01)

Obstacles to early treatment of idiopathic pulmonary fibrosis: current perspectives
by: Moua T, et al.
Published: (2019-01-01)

Left ventricular dysfunction in an idiopathic pulmonary fibrosis patient on nintedanib
by: Ryosuke Imai, et al.
Published: (2020-03-01)

Drug-Induced Thrombocytopenia Due to Nintedanib during Treatment of Idiopathic Pulmonary Fibrosis
by: Igor Dumic, et al.
Published: (2023-05-01)

Effect of nintedanib on non‐small cell lung cancer in a patient with idiopathic pulmonary fibrosis: A case report and literature review
by: Toshihiro Shiratori, et al.
Published: (2020-06-01)

Efficacy and safety of combination therapy with pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis
by: Jin-Young Huh, et al.
Published: (2023-12-01)

Aberrant B Cell Receptor Signaling in Naïve B Cells from Patients with Idiopathic Pulmonary Fibrosis
by: Stefan F. H. Neys, et al.
Published: (2021-05-01)

Thrombocytopaenia during nintedanib treatment in a patient with idiopathic pulmonary fibrosis
by: Yusuke Ochi, et al.
Published: (2020-10-01)

INTERSTITIAL LUNG DISEASES: KEY TARGETS FOR THERAPY
by: N. A. Shostak, et al.
Published: (2018-06-01)

Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
by: Hee-Young Yoon, et al.
Published: (2018-10-01)

Cost-effectiveness of the anti-fibrotics for the treatment of idiopathic pulmonary fibrosis in the United States
by: Timothy M. Dempsey, et al.
Published: (2022-01-01)

The Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis, Familial Pulmonary Fibrosis and Progressive Fibrosing Interstitial Lung Diseases: A Real-World Study
by: Paolo Cameli, et al.
Published: (2022-08-01)

Idiopathic pulmonary fibrosis: Physicians' perceptions of patient treatment with recently approved drugs
by: Céline Audibert, et al.
Published: (2016-08-01)

Comorbid Conditions in Idiopathic Pulmonary Fibrosis: Recognition and Management
by: Justin M. Oldham, et al.
Published: (2017-08-01)

Effects of Pirfenidone and Nintedanib on Markers of Systemic Oxidative Stress and Inflammation in Patients with Idiopathic Pulmonary Fibrosis: A Preliminary Report
by: Alessandro G. Fois, et al.
Published: (2020-10-01)

Impact of novel antifibrotic therapy on patient outcomes in idiopathic pulmonary fibrosis: patient selection and perspectives
by: Graney BA, et al.
Published: (2018-09-01)

Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme
by: Claudia Valenzuela, et al.
Published: (2020-01-01)

Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study [Letter]
by: Orsatti L, et al.
Published: (2019-04-01)

Antifibrotic treatment response and prognostic predictors in patients with idiopathic pulmonary fibrosis and exposed to occupational dust
by: Valeria Casillo, et al.
Published: (2019-09-01)

Temporal echocardiographic assessment of pulmonary hypertension in idiopathic pulmonary fibrosis patients treated with nintedanib with or without oxygen therapy
by: Masahiro Tahara, et al.
Published: (2019-08-01)

Choice of Methodology Impacts Outcome in Indirect Comparisons of Drugs for Idiopathic Pulmonary Fibrosis
by: David A. Scott, et al.
Published: (2019-08-01)

The effect of nintedanib on lung functions and survival in idiopathic pulmonary fibrosis: real-life analysis of the Czech EMPIRE registry
by: Marianna Štefániková, et al.
Published: (2023-05-01)

Clinical course and management of idiopathic pulmonary fibrosis
by: Caitlin Quinn, et al.
Published: (2019-12-01)

Diagnostic Approaches for Idiopathic Pulmonary Fibrosis
by: Jae Ha Lee, et al.
Published: (2024-01-01)

Differential diagnosis of idiopathic pulmonary fibrosis
by: E. I. Shmelev, et al.
Published: (2020-03-01)

Idiopathic pulmonary fibrosis: The current state of the problem
by: E I Shmelev
Published: (2016-12-01)

Anti-glomerular basement membrane glomerulonephritis following nintedanib for idiopathic pulmonary fibrosis: a case report
by: Ibrahim Ismail, et al.
Published: (2017-08-01)

Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
by: Kazutaka Takehara, et al.
Published: (2022-01-01)

Bibliometric analysis of the pirfenidone and nintedanib in interstitial lung diseases
by: Jia Liu, et al.
Published: (2024-04-01)

Historical eye on IPF: a cohort study redefining the mortality scenario
by: Sara Tomassetti, et al.
Published: (2023-06-01)

Nintedanib Inhibits Endothelial Mesenchymal Transition in Bleomycin-Induced Pulmonary Fibrosis via Focal Adhesion Kinase Activity Reduction
by: Wen-Kuang Yu, et al.
Published: (2022-07-01)

Clinicopathological Outlines of Post-COVID-19 Pulmonary Fibrosis Compared with Idiopathic Pulmonary Fibrosis
by: Roxana-Elena Cîrjaliu, et al.
Published: (2023-06-01)

Clinical Significance of Continuable Treatment with Nintedanib Over 12 Months for Idiopathic Pulmonary Fibrosis in a Real-World Setting
by: Kato M, et al.
Published: (2021-01-01)

Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials
by: Michael Kreuter, et al.
Published: (2019-04-01)

IDIOPATHIC PULMONARY FIBROSIS. CORRECTION OF ERRORS
by: A. L. Yudin, et al.
Published: (2018-12-01)

Lung Transplantation in Idiopathic Pulmonary Fibrosis
by: Rosalía Laporta Hernandez, et al.
Published: (2018-08-01)